Comment: The quality of evidence is downgraded by study limitations (poor reporting of methods).
A Cochrane review [Abstract] 1 included 22 studies (n=3171) assessing dopamine agonists in preventing ovarian hyperstimulation syndrome (OHSS) in assisted reproduction treatment. When compared with placebo or no intervention, dopamine agonists (cabergoline, quinagolide and bromocriptine) seemed effective in the prevention of moderate or severe OHSS (table T1). There was no difference in live birth rate, clinical pregnancy rate, multiple pregnancy rate or miscarriage rate (table T1).
Outcome | Relative effect(95% CI) | Risk with placebo/no intervention | Risk with intervention / Dopamine agonist (95% CI) | No of women(trials) Quality of evidence |
---|---|---|---|---|
Incidence of moderate or severe OHSS | OR 0.32(0.23 to 0.44) | 268 per 1000 | 105 per 1000(78 to 139) | 1202(10) Moderate |
Live birth rate | OR 0.96(0.60 to 1.55) | 324 per 1000 | 315 per 1000(223 to 426) | 362 (3) Low |
Clinical pregnancy rate | OR 0.92(0.63 to 1.37) | 307 per 1000 | 289 per 1000(218 to 377) | 530 (5) Low |
Date of latest search: 15 August 2016
Primary/Secondary Keywords